BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33968017)

  • 1. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.
    De Rienzo M; Foddai ML; Conti L; Mandoj C; Iaboni S; Saladini I; Castilletti C; Matusali G; Donno DR; Marchioni L; Ianniello S; Corpolongo A; Palange M; Ciliberto G; Piaggio G; De Marco F
    Front Immunol; 2021; 12():690322. PubMed ID: 34497602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2.
    Klingler J; Weiss S; Itri V; Liu X; Oguntuyo KY; Stevens C; Ikegame S; Hung CT; Enyindah-Asonye G; Amanat F; Baine I; Arinsburg S; Bandres JC; Kojic EM; Stoever J; Jurczyszak D; Bermudez-Gonzalez M; Nádas A; Liu S; Lee B; Zolla-Pazner S; Hioe CE
    J Infect Dis; 2021 Mar; 223(6):957-970. PubMed ID: 33367897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
    Ripoll JG; Tulledge-Scheitel SM; Stephenson AA; Ford S; Pike ML; Gorman EK; Hanson SN; Juskewitch JE; Miller AJ; Zaremba S; Ovrom EA; Razonable RR; Ganesh R; Hurt RT; Fischer EN; Derr AN; Eberle MR; Larsen JJ; Carney CM; Theel ES; Parikh SA; Kay NE; Joyner MJ; Senefeld JW
    mBio; 2024 May; 15(5):e0040024. PubMed ID: 38602414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
    Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
    Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
    Kenig A; Ishay Y; Kharouf F; Rubin L
    Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
    Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
    Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
    Gasser R; Cloutier M; Prévost J; Fink C; Ducas É; Ding S; Dussault N; Landry P; Tremblay T; Laforce-Lavoie A; Lewin A; Beaudoin-Bussières G; Laumaea A; Medjahed H; Larochelle C; Richard J; Dekaban GA; Dikeakos JD; Bazin R; Finzi A
    Cell Rep; 2021 Mar; 34(9):108790. PubMed ID: 33596407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.
    Verkerke H; Saeedi BJ; Boyer D; Allen JW; Owens J; Shin S; Horwath M; Patel K; Paul A; Wu SC; Wang J; Ho A; Maier CL; Zerra PE; Chonat S; Arthur CM; Roback JD; Neish AS; Lough C; Josephson CD; Stowell SR
    Transfusion; 2021 Jun; 61(6):1740-1748. PubMed ID: 34041759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.